Yi-Cheng Chen
7PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jul 02, 2025
Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare.Yi-Cheng Chen, Wen-Juei Jeng, Rong-Nan Chien
|Nov 07, 2023
Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.Yi-Cheng Chen, Chao-Wei Hsu, Rong-Nan Chien
|Aug 25, 2023
Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.Wen-Juei Jeng, Rong-Nan Chien, Yi-Cheng Chen
|Feb 11, 2021
Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients.Yi-Cheng Chen, Chao-Wei Hsu, Wen-Juei Jeng
|May 14, 2020
Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study.Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu
|Dec 02, 2017
Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.W-J Jeng, Y-C Chen, Y-F Liaw
Pageof 2
